Evidence map›Paper›PMID 25147191›Full record

ArticleG3 (Bethesda, Md.)2014

The alternative oxidase AOX does not rescue the phenotype of tko25t mutant flies.

Kia K Kemppainen, Esko Kemppainen, Howard T Jacobs

Open access · goldAbstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Kia K KemppainenBioMediTech and Tampere University Hospital, FI-33014 University of Tampere, Tampere, Finland.
Esko KemppainenBioMediTech and Tampere University Hospital, FI-33014 University of Tampere, Tampere, Finland.
Howard T JacobsBioMediTech and Tampere University Hospital, FI-33014 University of Tampere, Tampere, Finland Research Program of Molecular Neurology, FI-00014 University of Helsinki, Helsinki, Finland howard.t.jacobs@uta.fi.
Tampere University · FITampere University Hospital · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A point mutation [technical knockout(25t) (tko(25t))] in the Drosophila gene coding for mitoribosomal protein S12 generates a phenotype of developmental delay and bang sensitivity. tko(25t) has been intensively studied as an animal model for human mitochondrial diseases associated with deficiency of mitochondrial protein synthesis and consequent multiple respiratory chain defects. Transgenic expression in Drosophila of the alternative oxidase (AOX) derived from Ciona intestinalis has previously been shown to mitigate the toxicity of respiratory chain inhibitors and to rescue mutant and knockdown phenotypes associated with cytochrome oxidase deficiency. We therefore tested whether AOX expression could compensate the mutant phenotype of tko(25t) using the GeneSwitch system to activate expression at different times in development. The developmental delay of tko(25t) was not mitigated by expression of AOX throughout development. AOX expression for 1 d after eclosion, or continuously throughout development, had no effect on the bang sensitivity of tko(25t) adults, and continued expression in adults older than 30 d also produced no amelioration of the phenotype. In contrast, transgenic expression of the yeast alternative NADH dehydrogenase Ndi1 was synthetically semi-lethal with tko(25t) and was lethal when combined with both AOX and tko(25t). We conclude that AOX does not rescue tko(25t) and that the mutant phenotype is not solely due to limitations on electron flow in the respiratory chain, but rather to a more complex metabolic defect. The future therapeutic use of AOX in disorders of mitochondrial translation may thus be of limited value.

Indexed as

Adenosine TriphosphateAlternative OxidaseAnimalsbeta CaroteneCiona intestinalisDrosophilaDrosophila ProteinsElectron Transport Complex IEmbryonic DevelopmentFemaleGenotypeHormone AntagonistsMaleMifepristoneMitochondriaMitochondrial ProteinsAdenosine TriphosphateAlternative Oxidasebeta CarotenecitroxanthinDrosophila ProteinsElectron Transport Complex IHormone AntagonistsMifepristoneMitochondrial Proteinsmitochondrial ribosomal protein S12NADH DehydrogenaseOxidoreductasesPlant ProteinsReactive Oxygen SpeciesRibosomal Proteinsdevelopmental delaygene therapymitochondrial diseaseoxidative phosphorylationseizures

Identifiers

PMID25147191
PMCPMC4199707
OpenAlexW2152461224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.